Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, March 2009, p. 1268-1270, Vol. 53, No. 3
0066-4804/09/$08.00+0 doi:10.1128/AAC.01300-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Changes in aac(6')-Ib-cr Prevalence and Fluoroquinolone Resistance in Nosocomial Isolates of Escherichia coli Collected from 1991 through 2005
Gabriela Warburg,1
Maya Korem,1
Ari Robicsek,2
Dalia Engelstein,1
Allon E. Moses,1
Colin Block,1 and
Jacob Strahilevitz1*
Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University, Jerusalem 91120, Israel,1
Department of Medicine, Medical Center, NorthShore University HealthSystem, 2650 Ridge Ave., Evanston, Illinois 602012
Received 29 September 2008/
Returned for modification 14 November 2008/
Accepted 11 December 2008

ABSTRACT
Clinical isolates of
Escherichia coli collected from 1991 through
2005 at a tertiary-care center were studied for
qnr and
aac(6'
)-Ib-cr genes. Isolates bearing
aac(6'
)-Ib-cr emerged in 1998, coinciding
with an increase in ciprofloxacin resistance. The presence of
aac(6'
)-Ib-cr was multiclonal and was associated with the presence
of extended-spectrum β-lactamases.

INTRODUCTION
Plasmid-mediated
qnr and
aac(6'
)-Ib-cr genes confer reduced
quinolone susceptibility, facilitating the selection of chromosomal
mutations that confer high-level resistance (
7,
8,
15). Qnr
and Aac(6')-Ib-cr have therefore been hypothesized as potential
contributors to the increase in prevalence of quinolone resistance
among gram-negative bacteria. Epidemiological surveys have found
qnr genes in various
Enterobacteriaceae (
14). Findings from
a recent study suggest that
qnrA and
qnrB may have contributed
to the emergence of fluoroquinolone resistance among
Klebsiella pneumoniae and
Enterobacter spp. (
17). This survey also observed
an association between ceftazidime (CAZ) resistance and the
presence of
qnr genes, suggesting that in some species, the
frequent clinical association of cephalosporin resistance with
fluoroquinolone resistance might be due to the genetic linkage
of these two elements on plasmids.
The cr variant of aac(6')-Ib encodes an aminoglycoside acetyltransferase that confers reduced susceptibility to ciprofloxacin by the N-acetylation of its piperazinyl amine (15). Aac(6')-Ib-cr has two amino acid changes, Trp102Arg and Asp179Tyr, which together are necessary and sufficient for the enzyme's ability to acetylate ciprofloxacin. Several prior surveys of aac(6')-Ib-cr prevalence (5, 10, 12) were limited to cephalosporin- and/or ciprofloxacin-resistant isolates, which were collected over relatively short time frames. Hence, little is known about the epidemiological patterns of aac(6')-Ib-cr in population-representative clinical isolates over time. Interestingly, in two of these earlier studies aac(6')-Ib-cr was found predominantly in Escherichia coli. We therefore surveyed bloodstream isolates of E. coli collected over a 15-year period for aac(6')-Ib-cr and qnr genes in order to more broadly characterize the changes over time in the prevalence of these resistance elements in a large collection of clinical isolates. Additionally, we examined the isolates for evidence of an association between the genes of interest and CAZ resistance.
(This work was presented in part at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, 2008.)

Bacterial strains.
Since 1990 all patient-unique bloodstream isolates at Hadassah
Ein-Kerem Hospital in Jerusalem, Israel, have been preserved
at –70°C. For this study, we screened all available
nosocomial
E. coli isolates (i.e., isolated from cultures taken
>3 days after admission) from 1991 through 2005. Certain
isolates were unavailable due to nonsystematic clerical errors.

Susceptibility testing.
Disk susceptibility testing and clavulanic acid enhancement
of cephalosporin susceptibility for the detection of extended-spectrum
ß-lactamases (ESBLs) followed the recommendations of the
CLSI by using unsupplemented Mueller-Hinton agar and incubation
at 37°C for 16 to 20 h (
3).

Screening for plasmid-mediated quinolone resistance.
Screening for
qnr was carried out by multiplex PCR amplification
of
qnrA,
qnrB, and
qnrS as previously described (
16,
17).
Because Aac(6')-Ib-cr confers resistance to kanamycin, albeit at a level lower than that of Aac(6')-Ib (15), screening for aac(6')-Ib-cr was carried out in two steps; strains were screened for kanamycin susceptibility (Sigma Chemical Co., Rehovot, Israel) at a concentration of 32 µg/ml, followed by direct screening by gap-ligase chain reaction (LCR) for G535T, one of the two defining mutations of aac(6')-Ib-cr (15). Gap-LCR is a powerful method for detecting single base changes (1). For this technique, two same-directional primers, separated by a gap of several nucleotides, are chosen. These hybridize to complementary strands of target DNA and will be extended by DNA polymerase and subsequently ligated into a single long oligonucleotide when the mutation of interest, which corresponds to the 3' end of the first primer, is present. This oligonucleotide can then be amplified. We used as forward primers aac-glcr-F1 (5'-AGGTACCGTAACCACCCCAT) and aac-glcr-F2-P (5'/5Phos/GTCCAGCCGTGTACATGG), matching positions 516 to 535 and 539 to 556, respectively, with respect to the Aac(6')-Ib-cr translational starting point. Our reverse primers were aac-glcr-R3 (5'-CCATGTACACGGCTGGACC) and aac-glcr-R4-P (5'/5Phos/TGGGGTGGTTACGGTACCT) and were designed to amplify a 41-bp fragment corresponding to the oligonucleotide formed by the ligation of the forward primers. Bacterial DNA was prepared with a DNA isolation kit (Genekam Biotechnology AG, Duisburg, Germany). The four primers, at a concentration of 0.033 µM each, were added to the template DNA. Gap-LCR amplification was performed with AmpliTaq DNA polymerase Stoffel fragment (Applied Biosystems, Foster City, CA) at 0.033 U/µl, Taq DNA ligase (New England Biolabs, Beverly, MA) at 0.4 U/µl, and dATP, dTTP, and dGTP, each at 200 µM, in a final volume of 30 µl containing 1x Taq DNA ligase reaction buffer. The template concentration can play a major role in the specificity of the gap-LCR amplification procedures. By optimizing the assay conditions, we were able to use unquantified extracts of whole-cell DNA and maintain specificity. The gap-LCR conditions were 94°C for 30 s, 50°C for 30 s, 72°C for 5 s, and 60°C for 4 min, with a cycle number of 20. The amplification products were provisionally identified from their sizes in ethidium bromide-stained 16% polyacrylamide gels (Fig. 1). All strains that tested positive by gap-LCR were sequenced to confirm the presence of the G535T mutation and the T304C mutation. The gap-LCR assay was validated by assaying 10 strains known by sequencing to carry the aac(6')-Ib-cr gene, as well as 8 negative isolates, among which were isolates carrying the wild-type aac(6')-Ib gene. Gap-LCR gave correct results for all 18 isolates.

PFGE.
Pulsed-field gel electrophoresis (PFGE) after restriction with
XbaI was performed according to a standardized protocol (
13)
on all
aac(6'
)-Ib-cr+ isolates. The band patterns were analyzed
according to accepted criteria (
18).

Detection of ESBL genes by PCR.
Amplification of the major ESBL resistance determinants was
performed for all strains exhibiting an ESBL phenotype using
previously validated primers for the detection of
blaTEM (
9),
blaSHV (
6), and two sets of primers for
blaCTX-M genes (
11).

Statistical methods.
Fisher's exact test (
http://www.langsrud.com/fisher.htm) was
used to compare the prevalence of ciprofloxacin resistance (defined
as a MIC of

2 µg/ml) (
3),
aac(6'
)-Ib-cr, and
qnr before
and after 1 January 1998. The confidence intervals for the risk
ratios were calculated at
http://www.cebm.utoronto.ca/practise/ca/statscal/.

Results.
From 1991 through 2005, there were 904 episodes of nosocomial
E. coli bloodstream infection and 718 isolates were available
for analysis. From 1991 through 1997, 27 of 265
E. coli (11.3%)
isolates were ciprofloxacin intermediate or resistant, compared
with 144 of 453 (46.6%) from 1998 through 2005 (
P < 0.001)
(Fig.
2). From 1991 through 1997, no isolate had
aac(6'
)-Ib-cr,
whereas from 1998 onwards, 32 of 453 (7.1%) of the isolates
had
aac(6'
)-Ib-cr (
P < 0.001) (Fig.
2). Among the
aac(6'
)-Ib-cr+ isolates, 30 of 32 (93.8%) were not susceptible to ciprofloxacin.
PFGE of all the
aac(6'
)-Ib-cr+ strains demonstrated a cluster
of five indistinguishable isolates and an identical pair with
a different pattern, while the remaining 25 isolates were unrelated
(Fig.
3). A single isolate from 2002 harbored
qnrA. The genes
qnrB and
qnrS were not found. Thus,
aac(6'
)-Ib-cr was the predominant
plasmid-mediated quinolone resistance gene in
E. coli, and its
polyclonal emergence coincided with the rise in ciprofloxacin
resistance. Unlike
qnr genes in other
Enterobacteriaceae (
17),
the presence of the
aac(6'
)-Ib-cr gene was strongly associated
with ciprofloxacin resistance defined by CLSI criteria.
The presence of
aac(6'
)-Ib-cr was also associated with CAZ resistance
(risk ratio, 5.8 [95% confidence interval, 3.9 to 8.4]). To
adjust for the potential confounding effect of an association
between fluoroquinolone resistance and CAZ resistance independent
of the
aac(6'
)-Ib-cr gene, isolates were stratified by quinolone
susceptibility (Table
1). The association between CAZ resistance
and
aac(6'
)-Ib-cr was present in both fluoroquinolone-susceptible
and -resistant
E. coli.
View this table:
[in this window]
[in a new window]
|
TABLE 1. Distribution of ciprofloxacin and ceftazidime susceptibilities among aac(6')-Ib-cr+ and aac(6')-Ib-cr E. coli isolatesa
|
A total of 25 of 32 (78%)
aac(6'
)-Ib-cr+ E. coli manifested
an ESBL phenotype. Of these, one isolate harbored both
blaSHV-12 and
blaCTX-M-15 genes. Two additional isolates contained
blaSHV-12.
Two groups of
blaCTX-M genes were identified in 22 strains.
One group consisted of two strains identified as CTX-M-25; sequence
analysis of five nonrelated isolates (by PFGE) that belonged
to the second group revealed that all were CTX-M-15. Seventeen
isolates also harbored
blaTEM that was further identified in
two strains as TEM-1. Thus, although
aac(6'
)-Ib-cr appeared
in different clones it was associated with a limited number
of ESBL-encoding genes.

Discussion.
The prevalence of quinolone resistance among nosocomial
Enterobacteriaceae increased, at a different rate for each genus, following the
introduction of ciprofloxacin into the Hadassah hospitals at
the end of 1989. We recently showed that this increase coincided
with the entry of the
qnr genes into the
K. pneumoniae and
Enterobacter spp. populations (
17). Using gap-LCR, an inexpensive technique
better suited to large-scale epidemiologic surveys than previous
surveillance methods (
2,
12), we demonstrated a similar pattern
of penetration of
aac(6'
)-Ib-cr into multiple clinical
E. coli clones, coincident with a rise in fluoroquinolone resistance
from 11% in 1997 to 37% in 2005. A caveat regarding any observational
study of this kind is that correlation does not prove causation.
Also, further studies are needed to determine whether these
observations hold up globally.
Of note, we also demonstrated an epidemiologic link between aac(6')-Ib-cr and CAZ resistance and found that a majority of aac(6')-Ib-cr+ isolates (22 out of 32 [68.8%]) harbored a CTX-M ESBL. To ascertain that these genes in our collection are located on the same plasmid was beyond the scope of this work. However, our findings support earlier suggestions of a linkage between aac(6')-Ib-cr and CTX-M ESBLs (4, 12) and raise the possibility that the use of ciprofloxacin—a widely prescribed fluoroquinolone in the world—is a driver of both fluoroquinolone resistance and the emergence of CTX-M ESBLs.

ACKNOWLEDGMENTS
This work was supported by grant Morasha 1833/07 from the Israel
Science Foundation to J.S.

FOOTNOTES
* Corresponding author. Mailing address: Department of Clinical Microbiology and Infectious Diseases, Hadassah Ein-Kerem, Jerusalem 91120, Israel. Phone: 972-50-894 6353. Fax: 972-2-641 9545. E-mail:
jstrahilevitz{at}hadassah.org.il 
Published ahead of print on 22 December 2008. 

REFERENCES
1 - Abravaya, K., J. J. Carrino, S. Muldoon, and H. H. Lee. 1995. Detection of point mutations with a modified ligase chain reaction (Gap-LCR). Nucleic Acids Res. 23:675-682.[Abstract/Free Full Text]
2 - Ambrozic Avgustin, J., R. Keber, K. Zerjavic, T. Orazem, and M. Grabnar. 2007. Emergence of the quinolone resistance-mediating gene aac(6')-ib-cr in extended-spectrum-β-lactamase-producing Klebsiella isolates collected in Slovenia between 2000 and 2005. Antimicrob. Agents Chemother. 51:4171-4173.[Abstract/Free Full Text]
3 - Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
4 - Coque, T. M., A. Novais, A. Carattoli, L. Poirel, J. Pitout, L. Peixe, F. Baquero, R. Canton, and P. Nordmann. 2008. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg. Infect. Dis. 14:195-200.[Medline]
5 - Endimiani, A., L. L. Carias, A. M. Hujer, C. R. Bethel, K. M. Hujer, F. Perez, R. A. Hutton, W. R. Fox, G. S. Hall, M. R. Jacobs, D. L. Paterson, L. B. Rice, S. G. Jenkins, F. C. Tenover, and R. A. Bonomo. 2008. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob. Agents Chemother. 52:2680-2682.[Abstract/Free Full Text]
6 - Hoffmann, H., E. Sturenburg, J. Heesemann, and A. Roggenkamp. 2006. Prevalence of extended-spectrum beta-lactamases in isolates of the Enterobacter cloacae complex from German hospitals. Clin. Microbiol. Infect. 12:322-330.[CrossRef][Medline]
7 - Jacoby, G. A., K. E. Walsh, D. M. Mills, V. J. Walker, H. Oh, A. Robicsek, and D. C. Hooper. 2006. qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob. Agents Chemother. 50:1178-1182.[Abstract/Free Full Text]
8 - Martinez-Martinez, L., A. Pascual, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351:797.[CrossRef][Medline]
9 - Monstein, H. J., A. Ostholm-Balkhed, M. V. Nilsson, M. Nilsson, K. Dornbusch, and L. E. Nilsson. 2007. Multiplex PCR amplification assay for the detection of blaSHV, blaTEM and blaCTX-M genes in Enterobacteriaceae. APMIS 115:1400-1408.[Medline]
10 - Park, C. H., A. Robicsek, G. A. Jacoby, D. Sahm, and D. C. Hooper. 2006. Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob. Agents Chemother. 50:3953-3955.[Abstract/Free Full Text]
11 - Pitout, J. D., N. Hamilton, D. L. Church, P. Nordmann, and L. Poirel. 2007. Development and clinical validation of a molecular diagnostic assay to detect CTX-M-type beta-lactamases in Enterobacteriaceae. Clin. Microbiol. Infect. 13:291-297.[CrossRef][Medline]
12 - Pitout, J. D. D., Y. Wei, D. L. Church, and D. B. Gregson. 2008. Surveillance for plasmid-mediated quinolone resistance determinants in Enterobacteriaceae within the Calgary Health Region, Canada: the emergence of aac(6')-Ib-cr. J. Antimicrob. Chemother. 61:999-1002.[Abstract/Free Full Text]
13 - Ribot, E. M., M. A. Fair, R. Gautom, D. N. Cameron, S. B. Hunter, B. Swaminathan, and T. J. Barrett. 2006. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet. Foodborne Pathog. Dis. 3:59-67.[CrossRef][Medline]
14 - Robicsek, A., G. A. Jacoby, and D. C. Hooper. 2006. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6:629-640.[CrossRef][Medline]
15 - Robicsek, A., J. Strahilevitz, G. A. Jacoby, M. Macielag, D. Abbanat, P. C. Hye, K. Bush, and D. C. Hooper. 2006. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat. Med. 12:83.[CrossRef][Medline]
16 - Robicsek, A., J. Strahilevitz, D. F. Sahm, G. A. Jacoby, and D. C. Hooper. 2006. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob. Agents Chemother. 50:2872-2874.[Abstract/Free Full Text]
17 - Strahilevitz, J., D. Engelstein, A. Adler, V. Temper, A. E. Moses, C. Block, and A. Robicsek. 2007. Changes in qnr prevalence and fluoroquinolone resistance in clinical isolates of Klebsiella pneumoniae and Enterobacter spp. collected from 1990 to 2005. Antimicrob. Agents Chemother. 51:3001-3003.[Abstract/Free Full Text]
18 - Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.[Medline]
Antimicrobial Agents and Chemotherapy, March 2009, p. 1268-1270, Vol. 53, No. 3
0066-4804/09/$08.00+0 doi:10.1128/AAC.01300-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Strahilevitz, J., Jacoby, G. A., Hooper, D. C., Robicsek, A.
(2009). Plasmid-Mediated Quinolone Resistance: a Multifaceted Threat. Clin. Microbiol. Rev.
22: 664-689
[Abstract]
[Full Text]